
Hosted by PwC's Health Industries
Listed under Health & Fitness, Business, Business › Management
Hosted by Glenn Hunzinger, US Health Industries Leader, the Next in Health podcast series offers insights on the most important issues facing pharma, medtech, and healthcare.
74 episodes · publishes fortnightly · latest 2026-07-30 · ~19 min/episode
Rank
#730
Substance
69.3
/ 100
Breakdown
Scored 2026-08
Updated monthly
General rank
#58 of 134
Across the index
#730 of 1878
Substance
Top 39%
outscores 61% of the index
PwC's Next in Health ranks #730 on The B2B Podcast Index with a substance score of 69.3 out of 100, scored across 4 recent episodes. It scores highest on guest caliber and insight density. Three well-credentialed PwC leaders with relevant operational depth: Derek Scoob (actuarial/med-econ focus leading a 20-year survey of 110M+ lives), Phil Slifani (pharmaceutical cost and innovation strategy), Tom Bails (30+ years healthcare services experience, revenue cycle and policy expertise). These are practitioners with institutional authority and direct market access, though all are from a single firm perspective. They demonstrate genuine expertise in their domains but lack the diversity of external practitioners (hospital CFO, payer chief medical officer, employer benefit manager) that would strengthen guest caliber.
Averaged across 4 recently scored episodes, with cited evidence.
The episode delivers solid baseline data and frameworks (55% labor costs, 90% of costs from chronic illness, 60% from hospitals/physicians) but relies heavily on frameworks and categories already well-known in healthcare finance. Novel insights are limited: the AI/coding arms race angle is fresh and substantive, but much of the discussion retreads familiar ground (GLP-1 utilization vs. price tradeoffs, behavioral health underinvestment, consolidation leverage). The discussion of No Surprises Act arbitration outcomes (88% provider win rate) is concrete and notable, but the episode doesn't push beyond surface-level explanation of why this is happening or what to do about it.
“55% of those costs are labor-related costs”
“90% of the total costs relate to patients with chronic and mental illness”
The episode largely recycles established narratives: consolidation driving costs, AI as cost driver, GLP-1 coverage decisions, behavioral health expansion, cell/gene therapy as emerging expensive innovation. The most original element is the detailed unpacking of the AI/coding arbitrage - framing it as an 'arms race' between provider documentation AI and payer validation AI - but even this is presented as emerging trend commentary rather than novel framework. The No Surprises Act arbitration data is relatively fresh reporting, but analysis remains descriptive rather than generative of new thinking.
“it becomes a bit of AI facing off on AI, validating benefits, medical policies”
“There's a long history of when there are changes in reimbursement or laws and policies that the participants in healthcare change to optimize for the economics”
Three well-credentialed PwC leaders with relevant operational depth: Derek Scoob (actuarial/med-econ focus leading a 20-year survey of 110M+ lives), Phil Slifani (pharmaceutical cost and innovation strategy), Tom Bails (30+ years healthcare services experience, revenue cycle and policy expertise). These are practitioners with institutional authority and direct market access, though all are from a single firm perspective. They demonstrate genuine expertise in their domains but lack the diversity of external practitioners (hospital CFO, payer chief medical officer, employer benefit manager) that would strengthen guest caliber.
“surveyed and interviewed chief actuaries and med-econ leaders at more than two dozen U.S. health plans”
“30 plus years of experience”
The episode includes concrete figures throughout: $6 trillion total US healthcare spend, 55% labor, 90% chronic/mental illness, 70% comorbidity, 60% hospital/physician costs, 110M+ lives surveyed, 100M+ employer-sponsored members, 8M ACA members, 88% provider win rate on No Surprises arbitration, GLP-1 price declines of 60-70%, potential 2-4x volume increases, $30-50 PMPM for GLP-1 coverage. However, specificity drops when discussing solutions and trend impacts - vague language around 'creative solutions,' 'a lot of these individual treatments,' and 'small PMPM impact' that accumulates. Few named companies, specific health systems, or plan examples.
“almost six trillion dollars”
“surveyed and interviewed chief actuaries and med-econ leaders at more than two dozen U.S. health plans”
Glenn Hunzinger functions as a moderator rather than a probing interviewer, largely cueing prepared remarks from panelists with softlob setup questions ("demystify that a little bit," "maybe talk a little bit about that too"). Follow-ups are rare and rarely challenge claims; when disagreement or tension surfaces (e.g., around utilization management's risks), the host acknowledges rather than presses. The structure feels more like a curated report walk-through than genuine dialogue. Tom Bails does occasionally offer substantive pushback on his own arguments (e.g., acknowledging bias in arbitration could cut both ways), but the host doesn't weaponize this tension. Questions tend to invite monologue rather than debate.
“Maybe for the listeners here, you know, just unpack in simple form what is it”
“Phil, you always love a hard question. So I'm gonna throw one at you”
2 periods tracked.
4 scored on substance · 61 tracked in total.
Behind the Numbers 2027: Understanding what's driving healthcare costs - and what it means for the future of healthcare
2026-07-30 · 35 min
US Medtech Deals Midyear Outlook 2026: Why companies are investing through uncertainty
2026-06-25 · 12 min
US Health Services Deals Midyear Outlook 2026: Why investors are focusing on resilience and value creation
2026-06-25 · 9 min
US Pharma Deals Midyear Outlook 2026: Why Dealmakers Are Leaning Into Growth
2026-06-24 · 14 min
Add this badge to your site - it links back here and updates automatically as you rank.
<a href="https://index.fame.so/show/pwc-39-s-next-in-health" target="_blank" rel="noopener">
<img src="https://index.fame.so/badge/pwc-39-s-next-in-health/badge.svg" alt="Ranked #58 on The B2B Podcast Index" width="360" height="136" />
</a>Track PwC's Next in Health's rank
Get an email whenever this show moves up or down the Index. Monthly at most, no spam.
Companies, products and tools that come up most across this show's episodes.
The themes that come up most across this show's episodes.
CareTalk: Healthcare. Unfiltered.
CareTalk: Healthcare. Unfiltered.
Money Code
Stablecon
Reshaping Workflows with Dell Pro Precision and NVIDIA RTX PRO GPUs
Dell Technologies AI Factory with NVIDIA
The RAG Podcast
Sean Anderson
Outthinkers
Outthinker
Business Scholarship Podcast
Andrew Jennings
Podcasts that dig into the same topics.